These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28525528)

  • 1. Sevelamer versus calcium-based phosphate binders for chronic kidney disease.
    Bravo-Soto GA; Madrid T
    Medwave; 2017 May; 17(Suppl2):e6942. PubMed ID: 28525528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial.
    Ko SM; Zhang C; Chen Z; D'Marco L; Bellasi A; Stillman AE; Block G; Raggi P
    J Nephrol; 2016 Oct; 29(5):683-90. PubMed ID: 27102490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
    Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral phosphate binders in patients with kidney failure.
    Tonelli M; Pannu N; Manns B
    N Engl J Med; 2010 Apr; 362(14):1312-24. PubMed ID: 20375408
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
    PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
    Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
    Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
    Assimon MM; Mousa S; Shaker O; Pai AB
    Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.
    Jamal SA; Fitchett D; Lok CE; Mendelssohn DC; Tsuyuki RT
    Nephrol Dial Transplant; 2009 Oct; 24(10):3168-74. PubMed ID: 19622572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoeconomic analysis of phosphate binders cost-effectiveness in the RISCAVID study.
    Panichi V; Rosati A; Di Giorgio A; Scatena A; Bigazzi R; Grazi G; Migliori M; Paoletti S; Manca Rizza G; Casani A; Sgambato A; Ruggeri M
    Blood Purif; 2015; 39(1-3):174-180. PubMed ID: 25765293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.